What is the recommended dosage and usage of ceftazidime for treating severe Gram-negative bacterial infections in adults with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftazidime Dosing in Adults with Severe Gram-Negative Infections and Renal Impairment

For severe Gram-negative infections in adults with impaired renal function, ceftazidime requires mandatory dose reduction based on creatinine clearance, with a loading dose of 1 gram followed by adjusted maintenance dosing: 1 gram every 12 hours for CrCl 31-50 mL/min, 1 gram every 24 hours for CrCl 16-30 mL/min, 500 mg every 24 hours for CrCl 6-15 mL/min, and 500 mg every 48 hours for CrCl <5 mL/min. 1

Standard Dosing for Normal Renal Function

For adults with normal renal function (CrCl >50 mL/min), the dosing varies by infection severity: 1

  • Serious infections (complicated UTI, pneumonia, skin/soft tissue): 500 mg to 1 gram IV every 8 hours 1
  • Severe life-threatening infections (including immunocompromised patients, meningitis, serious intra-abdominal/gynecologic infections): 2 grams IV every 8 hours 1
  • Pseudomonas lung infections in cystic fibrosis: 30-50 mg/kg IV every 8 hours (maximum 6 grams/day) 1

Renal Dose Adjustment Algorithm

Critical principle: Ceftazidime is excreted almost exclusively by glomerular filtration, making dose reduction essential in renal impairment to prevent drug accumulation and neurotoxicity. 1, 2

Step-by-Step Dosing Approach:

  1. Administer loading dose: Give 1 gram IV regardless of renal function 1

  2. Calculate creatinine clearance using Cockcroft-Gault equation: 1

    • Males: CrCl = [Weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
    • Females: 0.85 × male value
  3. Apply maintenance dosing based on CrCl: 1

    • CrCl 31-50 mL/min: 1 gram every 12 hours
    • CrCl 16-30 mL/min: 1 gram every 24 hours
    • CrCl 6-15 mL/min: 500 mg every 24 hours
    • CrCl <5 mL/min: 500 mg every 48 hours
  4. Important caveat: If the standard dose for the infection type (from Table 3 in FDA labeling) is lower than the renal-adjusted dose, use the lower dose 1

Dialysis Considerations

  • Hemodialysis patients: Give 1 gram loading dose, then 1 gram after each dialysis session 1
  • Peritoneal dialysis/CAPD: Give 1 gram loading dose, then 500 mg every 24 hours; can incorporate 250 mg per 2L of dialysis fluid 1
  • Ceftazidime is removed by both hemodialysis and peritoneal dialysis, necessitating post-dialysis supplementation 1, 2

Modern Context: Ceftazidime-Avibactam Preferred for Resistant Organisms

While traditional ceftazidime remains effective for susceptible Gram-negative bacteria 2, 3, 4, current guidelines strongly favor newer agents for multidrug-resistant organisms: 5

For Carbapenem-Resistant Enterobacterales (CRE):

  • First-line: Ceftazidime-avibactam 2.5 g IV every 8 hours (over 2-3 hours) 6, 7
  • Alternatives: Meropenem-vaborbactam or imipenem-cilastatin-relebactam 5, 7

Ceftazidime-Avibactam Renal Dosing:

For CrCl >50 mL/min: 2.5 g every 8 hours; dose reductions required for moderate-severe renal impairment per FDA labeling to prevent neurotoxicity 6

Special Scenario - MBL-Producing Organisms:

Combination therapy with ceftazidime-avibactam plus aztreonam is strongly recommended for metallo-β-lactamase producers, as avibactam does not inhibit class B enzymes 5, 7

Critical Safety Monitoring

  • Neurotoxicity risk: Monitor for seizures, encephalopathy, and confusion, particularly in renal impairment where beta-lactam accumulation occurs 6
  • Therapeutic drug monitoring: Consider in severe infections with renal dysfunction 1
  • Duration: Continue for 2 days after clinical resolution; complicated infections may require longer courses 1

Key Clinical Pitfalls to Avoid

  1. Never skip the loading dose in renal impairment—it ensures rapid therapeutic levels 1
  2. Avoid using traditional ceftazidime monotherapy for suspected CRE—resistance rates are high and newer agents show superior outcomes 5
  3. Do not use standard dosing in dialysis patients—ceftazidime is significantly removed during dialysis sessions 1
  4. Extended infusions (3 hours) may be necessary for severe infections or augmented renal clearance to optimize PK/PD targets 5, 8

Related Questions

What does Ceftazidime (ceftazidime) cover that Ciprofloxacin (ciprofloxacin) does not?
What bacteria does Ceftazidime (ceftaz) cover?
What is the oral equivalent of Ceftazidime (a third-generation cephalosporin antibiotic) for a patient requiring broad-spectrum activity, including coverage against Pseudomonas aeruginosa?
What is the use of ceftazidime?
What is the oral equivalent of ceftazidime (a third-generation cephalosporin)?
Can heart failure cause dilutional hyponatremia?
What are the variations in citrate concentration in dialysate for patients undergoing hemodialysis and how much citrate remains after a dialysis session?
Is metformin (metformin hydrochloride) 500mg once daily or twice daily more effective for managing lipid profiles in a patient with mild Polycystic Ovary Syndrome (PCOS) and metabolic abnormalities, who previously showed improvement in lipid panel results after taking metformin 500mg daily for 7-8 weeks?
What is the most likely diagnosis for a 47-year-old male with a history of high sun exposure, new onset headaches that are worse in the mornings, personality changes, ataxic gait, and visual field deficits, who also has a new lesion behind his right ear and posterior auricular lymphadenopathy, with a past medical history of asthma, type 2 diabetes, and hypertension?
What is the diagnostic workup and treatment for a patient suspected of having scrofuloderma?
What is the appropriate treatment approach for an older patient with a thalamocapsular infarct and a history of vascular risk factors such as hypertension, diabetes, or hyperlipidemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.